Encompass Health saw a welcome improvement to its Relative Strength (RS) Rating on Wednesday, rising from 80 to 86.
This exclusive rating from Investor's Business Daily measures share price action with a 1 (worst) to 99 (best) score. The rating shows how a stock's price movement over the trailing 52 weeks stacks up against all the other stocks in our database.
Decades of market research shows that the best stocks tend to have an RS Rating of above 80 as they begin their biggest climbs.
Looking For The Best Stocks To Buy And Watch? Start Here
Encompass Health has climbed more than 5% past a 94.22 entry in a first-stage cup with handle, meaning it's now out of a proper buy range. Look for the stock to offer a new chance to get in like a three-weeks tight or pullback to the 50-day or 10-week line.
Encompass Health saw both earnings and sales growth rise last quarter. Earnings-per-share increased from 17% to 20%. Revenue rose from 10% to 12%.
Encompass Health holds the No. 1 rank among its peers in the Medical-Outpatient/Home Care industry group. Encompass Health and RadNet are also among the group's highest-rated stocks.
RELATED:
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
